Considerations for treatment duration in responders to immune checkpoint inhibitors
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“long-term PD-1 blockade predisposes patients to a higher risk of irAEs and increased financial burden without a proven effect on outcomes129.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz011 · Cited by 945
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.6620 · Cited by 912
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30436-8 · Cited by 751
Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1263 · Cited by 699
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Huang, A. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P. K., Manne, S., Kraya, A. A., Wubbenhorst, B., Dorfman, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0357-y · Cited by 686
Medical Care Costs Associated with Cancer Survivorship in the United States
Mariotto, A. B., Enewold, L., Zhao, J., Zeruto, C. A., & Yabroff, K. R. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1534 · Cited by 634
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Atkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Schadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Chesney, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2289 · Cited by 441
Ascierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 432
Couey, M. A., Bell, R. B., Patel, A. A., Romba, M. C., Crittenden, M. R., Curti, B. D., Urba, W. J., & Leidner, R. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0645-6 · Cited by 243
Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Hoejberg, L., Schmidt, H., van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz110 · Cited by 226
Financial toxicity and implications for cancer care in the era of molecular and immune therapies
Tran, G., & Zafar, S. Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.28 · Cited by 214
Forschner, A., Battke, F., Hadaschik, D., Schulze, M., Weißgraeber, S., Han, C.-T., Kopp, M., Frick, M., Klumpp, B., Tietze, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0659-0 · Cited by 198
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Betof Warner, A., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., Bajwa, R., Momtaz, P., Callahan, M. K., Wolchok, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01464 · Cited by 188
Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.
Andrews, A. (2015) · PubMed · Cited by 143
Wang, L. L., Patel, G. A., Fuxench, Z. C. C., McGettigan, S., Schuchter, L. M., Mitchell, T. C., Ming, M. E., & Chu, E. Y. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.1912 · Cited by 122
Spigel, D. R., McLeod, M., Hussein, M., Waterhouse, D. M., Einhorn, L. H., Horn, L., Creelan, B., Babu, S., Leighl, N. B., Couture, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.002 · Cited by 109
Hont, A. B., Cruz, C. C., Ulrey, R., O'Brien, B. J., Stanojevic, M., Datar, A. A., Albihani, S., Saunders, D., Hanajiri, R., Panchapakesan, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00177 · Cited by 83
The impact of corticosteroid use during anti-PD1 treatment
Pan, E. Y., Merl, M. Y., & Lin, K. I. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219872786 · Cited by 76
Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab
Yamaguchi, S., Morimoto, R., Okumura, T., Yamashita, Y., Haga, T., Kuwayama, T., Yokoi, T., Hiraiwa, H., Kondo, T., Sugiura, Y., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.007 · Cited by 75
Bernard‐Tessier, A., Baldini, C., Martin, P., Champiat, S., Hollebecque, A., Postel-Vinay, S. C., Varga, A., Bahleda, R., Gazzah, A., Michot, J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.005 · Cited by 67
Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy
Parakh, S., Cebon, J. S., & Klein, O. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0531 · Cited by 58
Diamantopoulos, P. T., Gaggadi, M., Kassi, E. N., Benopoulou, Ο., Anastasopoulou, A. N., & Gogas, H. J. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000355 · Cited by 32
The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma
Ladwa, R., & Atkinson, V. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000336 · Cited by 28
Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients
Iivanainen, S., & Koivunen, J. P. (2018) · Oncology · doi:10.1159/000493193 · Cited by 26
Khan, S., von Itzstein, M. S., Lü, R., Bermas, B. L., Karp, D. R., Khan, S. A., Fattah, F. J., Park, J. Y., Saltarski, J. M., Gloria-McCutchen, Y., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0666 · Cited by 26
Horiguchi, M., Uno, H., & Wei, L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0983 · Cited by 16
Duration of adjuvant immunotherapy—biologic, clinical and economic considerations
Stav, I., Gyawali, B., & Goldstein, D. A. (2018) · Medical Oncology · doi:10.1007/s12032-018-1218-0 · Cited by 16
Long-Lasting Responses under Treatment with Ipilimumab: An Argument against Maintenance Therapy?
Dick, J., Enk, A., & Hassel, J. C. (2014) · Dermatology · doi:10.1159/000365078 · Cited by 11
Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).
Shah, N. J., Ma, B. T., Kelly, W., Belouali, A., Serzan, M. T., Gonzalez, S. O., Colton, B., Janni, M. M., Knoedler, A. R., Blackburn, M. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15074 · Cited by 11
Pokorny, R., McPherson, J. P., Grossmann, K. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.10048 · Cited by 6
Cited by
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00224-8 · Cited by 421
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationSivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Metadata
- Authors
- Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., Olson, D., Naqash, A. R., Patel, R. B., Sachdev, E., Rodriguez-Ruiz, M. E., Sheffer, M., Church, S., Fuhrman, C., Overacre-Delgoffe, A., Nguyen, R., Florou, V., Thaxton, J. E., Aggen, D. H., & Guerriero, J. L.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- National University of Ireland (IE)
- The University of Texas Southwestern Medical Center (US)
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- Hummingbird Scientific (United States) (US)
- Johns Hopkins University (US)
- Vanderbilt University (US)
- Moffitt Cancer Center (US)
- University of Washington (US)
- University of Chicago (US)
- University of Pittsburgh (US)
- University of Southern California (US)
- Clinica Universidad de Navarra (ES)
- Dana-Farber Cancer Institute (US)
- Transitional Sciences, NanoString Technologies Inc, Seattle, Washington, USA
- Nanostring Technologies (United States) (US)
- National Cancer Institute (US)
- Huntsman Cancer Institute (US)
- Medical University of South Carolina (US)
- Memorial Sloan Kettering Cancer Center (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Guerriero, Jennifer L
- ORCID
- Marron, Thomas U
- Ryan, Aideen E
- Reddy, Sangeetha M
- Kaczanowska, Sabina
- Younis, Rania H
- Thakkar, Dipti
- Zhang, Jiajia
- Bartkowiak, Todd
- Howard, Rachel
- Anderson, Kristin G
- Olson, Daniel
- Naqash, Abdul Rafeh
- Patel, Ravi B
- Rodriguez-Ruiz, Maria E
- Sheffer, Michal
- Fuhrman, Christopher
- Overacre-Delgoffe, Abigail
- Nguyen, Rosa
- Florou, Vaia
- Thaxton, Jessica E
- Aggen, David H
- Guerriero, Jennifer L
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-03
- Volume
- 9
- Issue
- 3
- Pages
- e001901
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7929825
- OpenAlex
- W3134221665
- Cited by
- 137
- References
- 47
- Citations by year
- 2026: 13 · 2025: 31 · 2024: 21 · 2023: 36 · 2022: 31 · 2021: 5
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- SITC SPARKATHON
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- immune checkpoint inhibitors, treatment duration, durable response, overtreatment, financial toxicity, health-related quality of life, treatment response biomarkers, early clinical trials, metastatic melanoma, immunotherapy toxicity
- MeSH terms
- Immune Checkpoint Inhibitors, Clinical Trials as Topic, Drug Administration Schedule, Humans, Neoplasms, Risk Factors, Time Factors, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.